October 29, 2020 News by Marta Figueiredo, PhD MD1003 Fails to Prevent Disability Progression in Progressive MS Patients, Trial Shows MD1003, MedDay Pharmaceuticalsā high-dose biotin therapy, failed to significantly improve functional ability or walking speed in people with non-active progressiveĀ multiple sclerosis (MS), according to data from a Phase 3 clinical trial. Besides failing to meet the trialās goals, the therapy was associated with inaccurate results in…
March 13, 2020 News by Margarida Azevedo, MSc Second Phase 3 Trial of MedDay’s MD1003 for Progressive MS Fails to Meet Goals MedDay Pharmaceuticals‘Ā MD1003 did not ease functional disability or its progression in patients with non-active progressive multiple sclerosis, Phase 3 clinical trial data shows. The SPI2 Phase 3 study (NCT02936037) sought to confirm the positive results of a first Phase 3 trialĀ called MS-SPI…
January 31, 2019 Columns by Tamara Sellman Need to Know: High-dose Biotin Protocol Editor’s note: “Need to Know” is a series inspired by common forum questions and comments from readers. Have a comment or question about MS? Visit our forum. This week’s question is inspired by the forum topicĀ “Have you tried the high dose biotin protocol?“, from…
September 12, 2018 Columns by Mike Knight Out on a Stim: My FES Journey Comes to an End (Part 3) Third in a series. Read parts one and two. In March 2018, I began a personal research project ā quest if you will ā to assess how functional electrical stimulation (FES) devices might help me deal with the foot drop in my…
February 9, 2018 Columns by John Connor Do Supplements Add Up? It started with vitamin D. Little did I know I was starting a habit. I had my first sclerosis attack in 2006 and learned about it by having an appalling fall on a tennis court. That’s another story.Ā I haven’t written about that yet, but I’m sure I will.
February 8, 2018 News by Patricia Inacio, PhD #ACTRIMS2018 – MS Therapy MD1003’s Disability Improvements Hold Over Time, Study Shows MedDay Pharma’sĀ MD1003Ā leads to long-lasting improvements in progressive multiple sclerosis patients’ disability, a Phase 3 clinical trial follow-up study shows. Researchers presented the results at the thirdĀ Annual Americas Committee for Treatment and Research in Multiple Sclerosis ForumĀ in San Diego, Feb. 1-3. The poster presentation was titledĀ ā…
January 5, 2018 News by Patricia Silva, PhD Top 10 Multiple Sclerosis Articles of 2017 Multiple Sclerosis News Today brought you daily coverage of important discoveries, treatment developments, clinical trials, and other events dealing with multiple sclerosis throughout 2017. We look forward to providing more news to MS patients, family members, and caregivers during 2018. As a reminder of what mattered most to you in…
January 3, 2018 Columns by Mike Knight Turning Corners with MS: Ocrevus, Biotin, and 2018 Like a lot of people with MS, I took part in the āGreat Ocrevus Rush of 2017,ā with the fanfare surrounding the release of the first therapy in the United States known to have some ability to stem the advancement of primary and secondary progressive MS.
December 15, 2017 Columns by Ed Tobias Using Biotin? It Could Impact Your Lab Results Be careful if you’re using high-dose biotin (vitamin B7). The biotin in your blood could lead to some false readings when you have that blood tested. The level of concern about this is high enough to warrant aĀ warning from the U.S. Food and Drug Administration. High doses of biotin…
October 27, 2017 News by BioNews Staff #MSParis2017 ā Potential Progressive MS Treatment on Move in US and Europe, MedDay CEO Says This is a special edition of Multiple Sclerosis News Today's daily Alexa Flash Briefing, covering the latest news from the 7th Joint ECTRIMS-ACTRIMS Meeting currently underway in Paris, France. The MS News today team in on-site at the conference, providing exclusive coverage of the presentations and speakers.
October 26, 2017 News by Patricia Silva, PhD #MSParis2017 ā MedDayās High-Dose Biotin, MD1003, Improves Disability in Progressive MS Patients MD1003, a high-dose biotinĀ developed by MedDay, slowed or prevented further disease progression among progressive multiple sclerosis (MS) patients in a Phase 3 clinical trial, researchers announced at the Oct. 25ā28 7th Joint ECTRIMS-ACTRIMS Meeting in Paris, France. The effects of the treatment were seen to be upheld over…
August 15, 2017 Columns by Ed Tobias An MS Study You Might Want to Join I was surprised to see that a study of a potential MS drug labeled MD1003 is still accepting participants. It’s a study that I’d love to take part in, if only I was a few years younger. MD1003 is a high dose of biotin, a form of…
June 2, 2017 News by Patricia Silva, PhD #CMSC17 – Ocrevus, Progressive MS and Other Research Highlights: An Interview with CMSC’s Robert Lisak The recent annual meeting of theĀ Consortium of Multiple Sclerosis Centers (CMSC)Ā brought researchers and healthcare professionals to New Orleans to discuss advances ā and obstacles to advances ā in multiple sclerosis (MS) research. Clinical trials, preclinical studies, basic research, and health interventions were amongĀ the May meeting’s focus. Multiple Sclerosis News…
May 22, 2017 Columns by Ed Tobias MS News that Caught My Eye: Risk Factors, Biotin and Symptoms, Pills, Shots or IVs, and More In case you missedĀ them, here are some news stories that appeared in MS News Today that caught my eye over the past week. Ocrevus Market Entry Already Changing Dynamics in MS Treatment Choices, Spherix Analysis Suggests Are pills, shots, or infusions the therapy…
May 9, 2017 News by Patricia Silva, PhD MedDay’s New Phase 3 Trial and Belief in Biotin’s Potential to Treat Progressive MS: An Interview with Dr. FrĆ©dĆ©ric Sedel A global Phase 3 clinical trial assessingĀ MD1003 ā also known as high-dose biotin ā for progressive multiple sclerosis (MS) might lead to the approval of one of the first treatmentsĀ helping selectĀ progressive patients to improve. The trial aims to prove that high-dose biotin can reverse disability in non-active progressive MS.
December 19, 2016 Columns by Debi Wilson High dose biotin protocol – my nine month update! Nine months ago I started the high dose biotin protocol. I did so in an effort to slow the progression of my primary progressive multiple sclerosis. This is the link for my first article in August detailing the high dose biotin protocol and my results at that time.
August 29, 2016 Columns by Debi Wilson Riding the High-Dose Biotin Train for Progressive MS I knew of no available treatment options for my Primary Progressive MS, so when I heard about the pure High Dose Biotin Protocol I jumped on board! The protocol, created by MedDay in France, revolves around the vitamin Biotin (aka, vitamin B7 or H). It is recommended that the…
April 27, 2016 News by Patricia Silva, PhD MedDayās MD1003, a Biotin, Shows ‘Remarkable’ Efficacy in Treating Inactive but Progressive MS in Clinical Trials MedDayĀ recently disclosed full study results from the MS-SPI and MS-ON Phase 2b/3 trials ofĀ its therapeutic candidate MD1003 in patients with multiple sclerosis (MS). Specifically, the trials included people with “not active”Ā progressive MS and those with either relapsing or progressive MS andĀ visual loss, respectively. Data, presented at the recentĀ American…
October 13, 2015 News by Patricia Silva, PhD Insights into Promising MS Therapies at Late Breaking News Session, ECTRIMS 2015 A session titled āLate Breaking Newsā was featured at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 7-10, 2015, in Barcelona, Spain. At this session, Prof. Xavier Montalban from the Hospital Vall d’Hebron University in Barcelona presented data on the promising Genentech/Roche…
April 23, 2015 News by admin Phase III Study of Experimental MS Therapy Meets Primary Endpoint, Results to be Presented at ANN Meeting MedDay, a French biotechnology company that studies treatments for nervous system disorders, including multiple sclerosis, announced that MD1003, a highly-concentrated biotin, is effective forĀ treatment of progressive multiple sclerosis, according to results from a recent Phase III trial. MD1003 may have two beneficial effects: 1) increasing myelin, the fatty nerve-insulating…
April 8, 2015 News by Charles Moore MedDay Updates Status Of Pioneering Pivotal Phase III Study Design In Progressive Multiple Sclerosis MedDay, a Paris, France based biotechnology company specializing in treatment of neurological disorders, has released more information regarding the design of its (MS-SPI) clinical trial that is investigating the efficacy and safety of the investigational medicine MD1003 in treatment of primary and secondary progressive multiple sclerosis (MS). Progressive…